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BackgroundaaMultiple sclerosis (MS) is a demyelinating disease of the central nervous system. 
Secondary amyloidosis can occur as a complication of chronic systemic inflammatory and in-
fectious diseases. Until now there has been no report of secondary amyloidosis associated with 
MS. We report herein a case of renal biopsy-proven secondary amyloidosis in a patient with MS. 
Case ReportaaA 41-year-old woman with MS was hospitalized due to aggravated quadri-
paresis and edema in both lower extremities. Laboratory findings showed nephrotic-range pro-
teinuria and hypoalbuminemia. A percutaneous renal biopsy procedure was performed, the re-
sults of which revealed secondary amyloid-A-type amyloidosis associated with MS.   
ConclusionsaaThis is the first report of secondary amyloidosis associated with MS. 
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Multiple sclerosis (MS) is a demyelinating autoimmune dis-
ease of the central nervous system. Its pathological triad com-
prises central nervous system inflammation, demyelination, 
and gliosis.
1 Secondary amyloidosis, which develops seconda-
rily to chronic inflammatory conditions such as rheumatoid 
arthritis, is now called amyloid-A (AA) amyloidosis because 
a major factor in the protein deposition process involves a cl-
eaved product of the acute-phase protein, serum amyloid A 
(SAA).
2 Cerebrovascular amyloid deposits in the region of 
demyelinated plaques without systemic amyloidosis have 
been reported rarely in cases of MS;3 however, there is no 
report in the literature of MS related to AA amyloidosis. This 
article presents a case of MS with secondary AA amyloidosis, 
presenting with nephrotic syndrome. This is the first report of 




A 41-year-old Korean woman was hospitalized due to aggra-
vated quadriparesis. She had been diagnosed with MS at an 
age of 33 years. At 26 years of age, the patient experienced  
her first episode of quadriparesis with sensory changes in both 
lower extremities. At 33 years, she noticed decreased visual 
acuity for several days. At 40 years, she was admitted to the ho-
spital due to quadriparesis, dysarthria, and confusion, and her 
brain MRI showed brain, medullary, and spinal cord lesions 
(Fig. 1A) ; steroid pulse therapy was conducted. The patient’s 
neurological symptoms improved, and she was discharged. 
One year later, she was hospitalized again due to aggravated 
quadriparesis; she also complained of edema in both lower 
extremities. Steroid pulse therapy was performed again and 
the motor weakness in her upper extremities improved, but 
she continued to complain of dyspnea, orthopnea, and peri-
pheral edema. Her chest X-ray showed cardiomegaly with 
pulmonary edema, but her echocardiogram showed normal 
findings. Laboratory studies showed the following param-
eters: white blood cell count 6,500/mm
3, red blood cell count 
2.93×10
6/mm
3, hemoglobin 9.6 g/dL, hematocrit 28.1%, plate-
lets 248,000/mm
3, serum sodium 144 mEq/L, serum potas-
sium 4.7 mEq/L, serum chloride 109 mEq/L, serum creatinine 
1.2 mg/dL, serum blood urea nitrogen 78 mg/dL, serum al-
bumin 2.5 g/dL, serum total protein 5.0 g/dL, serum choles-
terol 218 mg/dL, and serum SAA 44.4 μg/mL  (reference 
level <8 μg/mL). In addition, anti-nuclear antibody, anti-neut-
rophil cytoplasmic antibody, rheumatoid factor, and cryoglo-
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also negative for hepatitis B surface antigen and anti-hepatitis-
C antibody. 
The 24-hour urinalysis revealed a protein excretion of 4,831 
mg/day. A percutaneous renal biopsy procedure confirmed the 
presence of AA-type amyloidosis (Fig. 1B-E). The patient had 
no family history of amyloidosis. We performed immunofixa-
tion electrophoresis on her serum and urine to exclude a plas-
ma-cell dyscrasia. M-proteins were not detected and hypoal-
buminemia was observed using serum immunofixation elect-
rophoresis. Urine immunofixation electrophoresis revealed al-
buminuria and increased globulin without an M-spike. AA 
amyloidosis was confirmed in view of the positive immunohis-
tochemical staining for amyloid A and negative staining for 
kappa and lambda; however, with the exception of a past his-
tory of non-febrile asymptomatic bacteriuria and a short-
lasting minor decubitus sore on the coccyx, there was no 
evidence of other systemic infection or inflammatory disease. 
Consequently, this case was diagnosed as secondary AA-type 
amyloidosis associated with MS. 
Discussion 
 
We present herein the clinicopathological findings of a patient 
with MS who developed AA amyloidosis approximately 15 
years after the onset of MS. Amyloidosis is caused by the extra-
cellular deposition of pathologic, insoluble, fibrillar proteins 
in organs and tissues. Precursor proteins are known to change 
into fibrils through multiple mechanisms that differ among 
the various types of amyloid. Secondary amyloidosis is caus-
ed by the deposition of amyloid originating from SAA, which 
is an acute-phase protein produced in response to inflamma-
tion
4 and occurs most commonly among patients with chronic 
inflammatory diseases such as rheumatoid arthritis, juvenile 
rheumatoid arthritis, and inflammatory bowel disease.
5 Fa-
milial Mediterranean fever (FMF) is also an inflammatory dis-
ease characterized by episodic fever and serositis. Livneh et 
al.
6 reported the development of AA amyloidosis in up to 
90% of untreated FMF patients. A high prevalence of FMF 
was recently reported in one MS cohort in Turkey.
7 These 
Fig. 1. MRI and microscopic findings. A:
Fluid-attenuated inversion recovery se-
quence on MRI showing three plaques 
in the brain, and T2-weighted MRI show-
ing severe atrophy of the cervical and 
thoracic cord. B: On light microscopy, the
glomerulus exhibits extensive efface-
ment of the glomerular architecture by la-
rge, irregularly shaped, amorphous, we-
akly periodic acid-Schiff (PAS)-positive, 
amyloid deposits (PAS ×400). C: Stron-
gly Congoredpositive materials can be 
seen in the glomeruli and arterioles (Co-
ngoed, ×400). D: Amyloid deposits are
positive on immunohistochemical stain-
ing for AA. E: Note the large nodular me-
sangial deposition of nonbranching, th-
in fibrils, ranging from 8.33 to 13.1 nm in 
thickness (electron micrograph, ×25, 000).
A 
B  C 
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data suggest that MS is related to secondary amyloidosis, 
although until now there have been no reports of secondary 
amyloidosis in patients with MS. 
One previous study found that SAA levels were increased 
in the peripheral blood of patients with relapsing-remitting type 
MS. SAA plays an important role in the conversion of innate 
immunity into the acquired immune response present during 
periods of acute and chronic inflammation.
8 Therefore, in-
creases in levels of SAA in MS patients may be considered 
evidence of the role of inflammation in MS, and may be a 
precursor of amyloid fibrils. However, there are no reports of 
increased levels of SAA in asymptomatic bacteriuria or de-
cubitus sores. 
Amyloid may be deposited either locally or systemically. 
The precursor proteins differ from each other in their prima-
ry structure and function. The clinical presentations and symp-
toms dependupon the distribution pattern and the amount of 
amyloid deposited. Renal involvement, as in this case, can 
cause nephrotic syndrome. The main treatment protocol for 
AA amyloidosis is management of the underlying inflamma-
tory disease process, which usually focuses on the surgical 
debridement of inflammatory tissue, antibiotic treatment of 
infectious processes, anti-inflammatory medications (colchi-
cine and anti-tumor necrosis factor blockade), and immuno-
supp ressive (cyclophosphamide) agents.
9 However, these 
treatments, have not yet been established in randomized 
controlled studies. In our case, disease-modifying agents for 
MS (e.g., interferon-β, glatiramer acetate) could be consider-
ed for the treatment of MS-associated secondary amyloidosis. 
However, the effect of these agents has not yet been estab-
lished. 
There have been two previous reports of localized amyloid 
deposits in MS;5 however, there have been no reported cases 
of associated systemic amyloidosis. This is the first published 
case of secondary amyloidosis presenting as nephrotic synd-
rome associated with MS. 
The findings of this case suggest strongly that MS is a ch-
ronic inflammatory disease and that secondary amyloidosis 
can develop in MS. 
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